Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Sep 30, 2029 to Jul 31, 2029 Show 4 more changesShow less
    • Study completion pushed from Dec 31, 2029 to Dec 31, 2031
    • Eligibility criteria expanded, about 119 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 3 of 5 sites
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 8, 2025 to Sep 19, 2025
    • Site details revised at 5 of 5 sites
    v3
  3. Secondary endpoints: details revised at 4 of 5 entries
    • Study description expanded, about 17 words
    • Study title expanded, about 1 word
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
Trial Details
NCT Number NCT07140679
Lead Sponsor Emory University
Collaborators: National Cancer Institute (NCI), Coherus Oncology, Inc.
Conditions
(from sponsor)		 Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Related terms Colonic Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov